The first thought an Anavex investor might have with that LPC agreement was announced, would be that the company prepares for running a P3 Precision Medicine trial as the outcome of the P2b/3 trial.
I am confident all OBJECTIVES where met for such a trial to be well designed. Anavex is just having a bit of communications confusion over the difference between meeting endpoints and their own objectives.